Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients
CPT: Pharmacometrics & Systems Pharmacology · 2023
DOI: 10.1002/psp4.12966 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2023. Verfasst von Di Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijin…. Hauptthemen laut MEDLINE: Tacrolimus, Myasthenia Gravis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, the population pharmacokinetic (PK) characteristics together with the exposure‐response of tacrolimus in the treatment of MG remain largely unknown. In this study, we aimed to develop a population PK/pharmacodynamic (PK/PD) model of tacrolimus in patients with MG, in order to explore the relationships among tacrolimus dose, exposure, and its therapeutic efficacy. The genotype of CYP3A5, Osserman's classification, and status of thymus, as well as demographic characteristics and other biomarkers from laboratory testing were tested as covariate, and simulations were performed based on the final model. The population PK model was described using a one‐compartment model with first‐order elimination and fixed absorption parameters. CYP3A5 genotype significantly influenced the apparent clearance, and total protein (TP) influenced the apparent volume of distribution as covariates. The quantitative MG scores were characterized by the cumulated area under curve of tacrolimus in a maximum effect function. Osserman's classification was a significant covariate on the initial score of patients with MG. The simulations demonstrated that tacrolimus showed an unsatisfying effect possibly due to insufficient exposure in some patients with MG. A starting dose of 2 mg/d and even higher dose for patients with CYP3A5 *1/*1 and *1/*3 and lower TP level were required for the rapid action of tacrolimus. The population PK/PD model quantitatively described the relationships among tacrolimus dose, exposure, and therapeutic efficacy in patients with MG, which could provide reference for the optimization of tacrolimus dosing regimen at the individual patient level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual A…
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- Department of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Zitieren
APA
Chen, D., Yao, Q., Chen, W., Yin, J., Hou, S., Tian, X., Zhao, M., Zhang, H., Yang, L., Zhou, T., & Jin, P. (2023). Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.12966
Vancouver
Chen D, Yao Q, Chen W, Yin J, Hou S, Tian X, et al. Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients. CPT: Pharmacometrics & Systems Pharmacology. 2023. doi:10.1002/psp4.12966
BibTeX
@article{Chen2023,
author = {Chen, Di and Yao, Qingyu and Chen, Wenjun and Yin, Jian and Hou, Shifang and Tian, Xiaoxin and Zhao, Ming and Zhang, Hua and Yang, Liping and Zhou, Tianyan and Jin, Pengfei},
title = {Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2023},
doi = {10.1002/psp4.12966}
}
EUVIMED